Creative Medical Technology (NASDAQ:CELZ) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Creative Medical Technology (NASDAQ:CELZ) to a hold rating in a research report released on Saturday.

Other equities analysts have also recently issued reports about the company. Zacks Research upgraded Creative Medical Technology to a “hold” rating in a research report on Tuesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Creative Medical Technology in a report on Monday, December 1st. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Creative Medical Technology currently has a consensus rating of “Reduce”.

Creative Medical Technology Trading Up 5.4%

Creative Medical Technology stock opened at $2.34 on Friday. Creative Medical Technology has a 1-year low of $1.69 and a 1-year high of $6.90. The firm has a market capitalization of $6.04 million, a PE ratio of -0.80 and a beta of 2.06. The firm’s 50 day simple moving average is $3.25 and its 200 day simple moving average is $2.99.

Creative Medical Technology (NASDAQ:CELZ) last released its quarterly earnings results on Friday, November 7th. The company reported ($0.48) EPS for the quarter, meeting analysts’ consensus estimates of ($0.48). Research analysts forecast that Creative Medical Technology will post -3.19 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Creative Medical Technology stock. Armistice Capital LLC bought a new position in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 148,000 shares of the company’s stock, valued at approximately $321,000. Armistice Capital LLC owned about 3.38% of Creative Medical Technology at the end of the most recent quarter. 1.42% of the stock is owned by hedge funds and other institutional investors.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.